Last reviewed · How we verify
Buparlisib & Paclitaxel
Buparlisib inhibits PI3K signaling while paclitaxel stabilizes microtubules to prevent cell division, together targeting cancer cell proliferation through complementary pathways.
Buparlisib inhibits PI3K signaling while paclitaxel stabilizes microtubules to prevent cell division, together targeting cancer cell proliferation through complementary pathways. Used for Metastatic breast cancer (phase 3 development).
At a glance
| Generic name | Buparlisib & Paclitaxel |
|---|---|
| Also known as | AN2025 |
| Sponsor | Adlai Nortye Biopharma Co., Ltd. |
| Drug class | PI3K inhibitor (buparlisib) + taxane chemotherapy (paclitaxel) |
| Target | PI3K (buparlisib); β-tubulin (paclitaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Buparlisib is a pan-class I PI3K inhibitor that blocks phosphatidylinositol 3-kinase signaling, a pathway frequently dysregulated in cancer. Paclitaxel is a taxane that binds to β-tubulin and stabilizes microtubules, preventing mitotic spindle disassembly and inducing apoptosis. The combination exploits both growth signaling inhibition and direct cytotoxic mechanisms.
Approved indications
- Metastatic breast cancer (phase 3 development)
Common side effects
- Neutropenia
- Peripheral neuropathy
- Hyperglycemia
- Diarrhea
- Nausea/vomiting
- Fatigue
Key clinical trials
- The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC (PHASE3)
- Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer (PHASE1)
- A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab (PHASE1)
- NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer (PHASE2)
- Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer (PHASE1)
- Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy (PHASE2)
- BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors (PHASE1)
- A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |